MorphoSys News
Most Popular MorphoSys Story
ALSO NOTED: Endo buys Novartis' Voltaren; Microbia, Forest produce positive Phase III data; and much more...
> Endo Pharmaceutical is buying Novartis' Voltaren gel for $85 million upfront and a one-time sales milestone of $25 million. Read more...
Latest Headlines
- December 10, 2010
- November 26, 2008
- May 21, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
